Quadrant Capital Group LLC Eagle Pharmaceuticals, Inc. Transaction History

Quadrant Capital Group LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$17.74 - $31.87 $30,583 - $54,943	-1,724 Reduced 95.14%	88 $1,000
Q1 2023 May 11, 2023	BUY	$25.06 - $34.09 $24,057 - $32,726	960 Added 112.68%	1,812 $51,000
Q4 2022 Feb 10, 2023	BUY	$24.98 - $39.77 $6,245 - $9,942	250 Added 41.53%	852 $24,000
Q3 2022 Nov 10, 2022	BUY	$26.42 - $47.12 $14,372 - $25,633	544 Added 937.93%	602 $16,000
Q2 2022 Aug 09, 2022	SELL	$41.26 - $51.35 $2,805 - $3,491	-68 Reduced 53.97%	58 $3,000
Q1 2022 May 06, 2022	BUY	$44.58 - $52.6 $3,477 - $4,102	78 Added 162.5%	126 $6,000
Q4 2021 Feb 01, 2022	BUY	$45.82 - $56.9 $183 - $227	4 Added 9.09%	48 $2,000
Q3 2021 Nov 12, 2021	BUY	$43.79 - $55.78 $1,138 - $1,450	26 Added 144.44%	44 $2,000
Q2 2021 Aug 09, 2021	SELL	$36.86 - $44.5 $663 - $801	-18 Reduced 50.0%	18 $1,000
Q1 2021 May 12, 2021	BUY	$40.32 - $50.97 $645 - $815	16 Added 80.0%	36 $2,000
Q4 2020 Feb 16, 2021	BUY	$41.72 - $51.34 $166 - $205	4 Added 25.0%	20 $1,000
Q1 2020 May 15, 2020	BUY	$34.37 - $60.07 $549 - $961	16 New	16 $1,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.